EnsoData, a Madison, WI-based AI health care company helping clinicians uncover disease while patients sleep, closed a $20m Series A extension funding.
The round was led by Inspire Medical Systems, Inc. (NYSE: INSP), with participation from existing investors including Zetta Venture Partners, Venture Investors, Supermoon Capital, Colle Capital, HealthX Ventures, M25 Ventures, Board members Justin Mortara, Fred Robertson, MD, and other investors.
With this new funding, the company will scale multinational expansion and commercial distribution partnerships, continue building out its team, and expand its product offerings to address new customer use cases and features to enable more accurate, affordable, and accessible care globally.
Led by Chris Fernandez, CEO and Co-Founder, EnsoData is an AI healthcare technology company that performs complex and time-consuming data interpretation and analysis. Its FDA cleared, AI-assisted sleep scoring solution, EnsoSleep, automates the scoring of studies, and reduces the time sleep clinicians otherwise spend working through hours of sleep data. Additional products include EnsoViewer, an FDA cleared, web-based, interoperable sleep study reviewing, editing, and reporting software, and EnsoTST, which enables measurement of Total Sleep Time through more commonly available data found in home sleep apnea tests (HSATs).
Through partnerships with more than 100 provider organizations’ 500+ clinics across the U.S., over 500,000 patients have already used the technology.
The company is also expanding its leadership team with the appointment of Justin Mortara, PhD, as President. Coupled with funding and new partnerships, EnsoData’s latest additions to its senior leadership team will be essential as the company scales to accelerate the adoption of AI technology across healthcare.
FinSMEs
03/06/2022